Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Miikana Therapeutics
Fremont, California, United Statesmiikana.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Miikana Therapeutics built an oncology-focused pipeline through both internal discovery and in‑licensing strategies. Its assets included small molecule drug candidates such as an aurora kinase inhibitor and an HDAC inhibitor. The company received a worldwide license for MKC‑1 from Hoffmann-La Roche. In December 2005, it was acquired by EntreMed, Inc., which integrated its pipeline into broader multi-mechanism oncology and inflammation drug development efforts. Clinical results for individual compounds are not detailed in public sources; most programs were preclinical or early-stage at the time of acquisition.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Small moleculesHDAC inhibitorsaurora kinase inhibitors
- Industry
- Biotech
02
Partnerships
Exclusive worldwide license with Hoffmann-La Roche for MKC–1 development/manufacturing/commercialization rights prior to acquisition by EntreMed.
Beyond the preview
Go deeper on Miikana Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Miikana Therapeutics.